Drugs / ChiLob7/4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01561911 | Jul 2007 → Oct 2014 | B-cell neoplasm, cancer, non-Hodgkin lymphoma | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChiLob7/4 | “This phase I study aimed to establish the biologic effects and MTD of the agonistic IgG1 chimeric anti-CD40 antibody ChiLob7/4 in patients (pts) with a range of CD40-expressing...” PMID 25589626 ↗ Jan 2015 |
| Action | Activate | “the agonistic IgG1 chimeric anti-CD40 antibody ChiLob7/4” PMID 25589626 ↗ Jan 2015 |
| Route | Intravenous | “Chi Lob 7/4, given intravenously, weekly for 4 weeks” NCT01561911 ↗ |
| Target | CD40 | “the agonistic IgG1 chimeric anti-CD40 antibody ChiLob7/4” PMID 25589626 ↗ Jan 2015 |